

Advances in Lymphedema Management, Prevention, & Early Detection

1. Letellier ME, Ibrahim M, Towers A, Chaput G. Incidence of lymphedema related to various cancers. *Med Oncol*. 2024 Sep 17;41(10):245. doi: 10.1007/s12032-024-02441-2. PMID: 39289260; PMCID: PMC11408551.
2. Cabioglu N, Koçer HB, Karanlık H, Gülçelik MA, Igci A, Müslümanoğlu M, Uras C, Mantoglu B, Trabulus DC, Akgül G, Tükenmez M, Senol K, Özkurt E, Sen E, Karadeniz Çakmak G, Bademler S, Emiroglu S, Yildirim N, Kara H, Dag A, Dilege E, Altinok A, Basaran G, Varol E, Ugurlu Ü, Bölükbaşı Y, Ersoy YE, Zengel B, Karaman N, Özbas S, Zer L, Gül Kiliç H, Agcaoglu O, Sakman G, Utkan Z, Soyder A, Akcan A, Ergün S, Yilmaz R, Aydinler A, Soran A, Ibis K, Özmen V. De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer. *JAMA Surg*. 2025 Mar 1;160(3):257-266. doi: 10.1001/jamasurg.2024.5913. PMID: 39745737; PMCID: PMC11904723.
3. Deban M, McKinnon JG, Temple-Oberle C. Mitigating Breast-Cancer-Related Lymphedema-A Calgary Program for Immediate Lymphatic Reconstruction (ILR). *Curr Oncol*. 2023 Jan 24;30(2):1546-1559. doi: 10.3390/curroncol30020119. PMID: 36826080; PMCID: PMC9955571.
4. Rafn BS, McNeely ML, Camp PG, Midtgaard J, Campbell KL. Self-Measured Arm Circumference in Women With Breast Cancer Is Reliable and Valid. *Phys Ther*. 2019 Feb 1;99(2):240-253. doi: 10.1093/ptj/pty117. PMID: 30289500.
5. Larsen GS, Jensen S, Von Heymann A, Rafn BS. Self-measured leg circumference for the detection of lymphedema among men with prostate cancer: a reliability study. *Acta Oncol*. 2025 Feb 27;64:326-330. doi: 10.2340/1651-226X.2025.42249. PMID: 40013604; PMCID: PMC11884415.

Immunotherapy-Related Adverse Events: A Primer for Surgeons

1. http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Supportive%20Care/SCIMMUNE_Protocol.pdf
2. Schneider BJ, Naidoo J, Santomaso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. *J Clin Oncol*. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub

2021 Nov 1. Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315. doi: 10.1200/JCO.21.02786. PMID: 34724392.

3. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18. PMID: 36270461.
4. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomaso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021 Jun;9(6):e002435. doi: 10.1136/jitc-2021-002435. PMID: 34172516; PMCID: PMC8237720.
5. Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. 2020 Feb;47(2):166-175. doi: 10.3899/jrheum.190084. Epub 2019 Jul 15. PMID: 31308203.